A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...
Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes.
Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.
Researchers from the Critical Analytics for Manufacturing Personalized Medicine (CAMP), an interdisciplinary research group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), in ...
Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results